2014 full year results & corporate update, page-18

Dave said that the FDA would never drop a control arm "because patients can get a transplant or VAD."

So its not just deaths but equivalent deaths as well i.e.. VADs and transplants in trial.
Should the patients have the option of a C-Pulse since very few would get a transplant and VAD's??.

Dave didn't answer some quite reasonable questions I sent about C-Pulse 2.

Maybe the control arm has minimal deaths/transplants /VAD's but given the Class 3 market is in the millions and the Class 4 market is in the 100's of thousands, its highly likely people are bombing out big time in the control arm.